@article{TLCR28523,
author = {Maria A. Velez and Timothy F. Burns},
title = {Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {Suppl 4},
year = {2019},
keywords = {},
abstract = {The immune checkpoint inhibitor pembrolizumab, has been shown to be efficacious and to have significant and durable antitumor activity in a subset of patients with advanced non-small cell lung cancer (NSCLC). Most notably in NSCLC with high expression of the programmed death ligand-1 (PD-L1). Similarly, there is abundant data to support the use of epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy in patients whose tumors harbor EGFR mutations (1).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/28523}
}